Internal Medicine, Rheumatology · Dartmouth, MA
NPI
1326028085
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
3
Medicare group memberships
Hospitals
2
Hospital affiliations
535 Faunce Corner Rd
Dartmouth, MA, 02747
Phone (508) 996-3991
Groups this clinician bills Medicare through
Medicare paid, 2024
$692K
46,439 services
Medicare patients, 2024
694
Average age 73
Drug cost, 2024
$3.8M
8,590 prescriptions
Company payments, 2025
$2,314
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael Hait was code J0897 (injection, denosumab, 1 mg), 10,740 times for 114 patients. In total Michael Hait billed 46,439 services in 82 codes, and Medicare paid $692K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-08-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 10,740 | 114 | $19.90 | $214K |
| Q5103 Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | Office | 1,180 | 11 | $9.86 | $12K |
| 99213 Office E&M - Established | Office | 703 | 463 | $64.43 | $45K |
| 99214 Office E&M - Established | Office | 458 | 310 | $87.11 | $40K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 362 | 30 | $0.68 | $246 |
| 36415 Venipuncture Blood Collection | Office | 308 | 262 | $8.65 | $2,664 |
| 96372 Injection Administration | Office | 252 | 122 | $10.33 | $2,602 |
| J3489 Injection, zoledronic acid, 1 mg | Office | 190 | 38 | $5.06 | $961 |
| 86140 Clinical Chemistry | Office | 178 | 159 | $5.08 | $904 |
| 85652 Clinical Chemistry | Office | 153 | 134 | $2.65 | $405 |
| 99204 Office E&M - New | Office | 123 | 123 | $114.34 | $14K |
| 96365 Intravenous Infusion, Hydration | Office | 99 | 60 | $48.84 | $4,835 |
| 80053 Clinical Chemistry | Office | 98 | 91 | $10.14 | $994 |
| 96415 Chemotherapy Administration | Office | 80 | 18 | $21.60 | $1,728 |
| 96413 Chemotherapy Administration | Office | 70 | 19 | $99.88 | $6,992 |
By year: 2022 $486K for 27,357 services; 2023 $507K for 31,858 services; 2024 $692K for 46,439 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 308 | 262 | $8.65 | $2,664 |
| 86140 Clinical Chemistry | 178 | 159 | $5.08 | $904 |
| 85652 Clinical Chemistry | 153 | 134 | $2.65 | $405 |
| 80053 Clinical Chemistry | 98 | 91 | $10.14 | $994 |
| 85027 Blood Count | 64 | 61 | $6.29 | $403 |
| 82310 Clinical Chemistry | 41 | 41 | $4.81 | $197 |
| 80048 Clinical Chemistry | 38 | 31 | $8.29 | $315 |
| 81003 Clinical Chemistry | 29 | 29 | $2.20 | $63.8 |
| 84550 Clinical Chemistry | 26 | 24 | $4.43 | $115 |
| 80061 Clinical Chemistry | 20 | 20 | $13.12 | $262 |
Medicare prescription drug claims, 2024
In 2024, the drug Michael Hait prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 723 prescriptions and refills. In total Michael Hait wrote 8,590 Medicare prescriptions that cost $3.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 723 | 1,200 | 141 | $21K |
| Prednisone Generic | 565 | 752 | 134 | $3,712 |
| Gabapentin Generic | 541 | 661 | 84 | $7,666 |
| Tramadol Hcl Generic | 352 | 354 | 52 | $2,767 |
| Meloxicam Generic | 328 | 476 | 76 | $1,283 |
| Alendronate Sodium Generic | 289 | 688 | 86 | $2,700 |
| Duloxetine Hcl Generic | 203 | 327 | 37 | $3,982 |
| Methotrexate Methotrexate Sodium | 192 | 354 | 44 | $5,145 |
| Leflunomide Generic | 186 | 352 | 43 | $9,207 |
| Baclofen Generic | 185 | 265 | 43 | $3,432 |
| Celecoxib Generic | 170 | 230 | 43 | $7,159 |
| Diclofenac Sodium Generic | 170 | 204 | 70 | $3,832 |
| Cyclobenzaprine Hcl Generic | 165 | 179 | 34 | $1,212 |
| Methylprednisolone Generic | 154 | 160 | 107 | $1,068 |
| Pregabalin Generic | 152 | 156 | 22 | $3,822 |
Brand drugs: - claims; generic drugs: 7,723 claims; opioid claims: 701.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael Hait $2,314 ($2,314 in general payments such as food, travel and fees) from 13 companies. The largest payer was Abbvie Inc. with $887.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 45 | $887 |
| Amgen Inc. AMGN | 21 | $430 |
| Janssen Biotech, Inc. JNJ | 10 | $295 |
| UCB, Inc. UCB.BR | 9 | $204 |
| AstraZeneca Pharmaceuticals LP AZN | 9 | $176 |
| Genzyme Corporation SNY | 3 | $97.11 |
| GlaxoSmithKline, LLC. GSK | 3 | $53.32 |
| Tonix Medicines, Inc. | 2 | $37.44 |
| E.R. Squibb & Sons, L.L.C. BMY | 2 | $35.38 |
| Actelion Pharmaceuticals US, Inc. JNJ | 2 | $32.8 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.